News
Anika Therapeutics Inc (NASDAQ: ANIK) announced that Cingal met its primary endpoint in a Phase 3 Study (Cingal 19-01), demonstrating superiority over triamcinolone hexacetonide (TH) steroid alone ...
By Reuters May 25, 20175:40 PM UTCUpdated ago May 25 (Reuters) - Anika Therapeutics Inc: * Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback